AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Primary Objective
This study is looking for a patients who have been diagnosed with Acute Myeloid Leukemia (AML) and this AML has a specific genetic change, also called a mutation, in a protein called IDH2.
Description
The overall goals of this study are to: - Find out what effects, good and/or bad, enasidenib has on people with your AML cancer and IDH2 mutation. - To learn more about the side effects of enasidenib The study of enasidenib in children and young adults with AML is investigational. This study is a ‘feasibility’ study, meaning that results from the study may be incorporated into future treatment plans.
Details
Locations
Childrens Hospital Colorado
Principal Investigator
Margaret Macy
Study ID
Protocol Number: 20-3065
More information available at ClinicalTrials.gov: NCT04203316
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers